Alzheimer’s prevention Phase 1 trial will look at safety of nasal vaccine. Much to happen before any conclusions can be drawn from this study. Also, @billcarrolltalk and I also discuss the approval of COVID vaccine for 5-11 year-old children.

Dr. Barry Dworkin

Medical Mythbusting Commentary for November 22, 2021

Alzheimer's prevention Phase 1 trial will look at safety of nasal vaccine. Much to happen before any conclusions can be drawn from this study. Also, @billcarrolltalk and I also discuss the approval of COVID vaccine for 5-11 year old children. Play Now | Play in Popup | Download

Source:
Nasal vaccine to treat Alzheimer’s disease to be tested in U.S. clinical trial

COVID-19 vaccines for children

Related posts:

  1. CDC study shows vaccines cut Covid infections and transmission. They will help get us out of the pandemic.
  2. Give research the time to answer the question about the need for yearly Covid-19 vaccine boosters given that variants, present and future, will continue to be an issue for a while. Speculation is a mug’s game. Evidence is better.
  3. What should your #seconddose of #covidvaccine be if 1st was AZ? Factors include wait-time/availability, Delta variant prevalence, occupational risks, and study evidence. Answer seems to leaning to Pfizer or Moderna as 2nd dose of choice.
  4. The three reasons for mRNA COVID vaccine medical exemptions are documented allergy to polyethylene glycol, or after the first vaccine dose, severe allergic reactions or myocarditis. Physicians advised not to provide notes for invalid reasons.
Bitnami